JJ
VOR icon

Johnson & Johnson’s Vor Biopharma VOR Stock Holding History

Johnson & Johnson’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$989K Hold
53,732
– – 0.12% 13
2026
Q1 		$959K Hold
53,732
– – 0.15% 13
2025
Q4 		$703K Hold
53,732
– – 0.13% 14
2025
Q3 		$2.62M Sell
53,732
-1
-0% -$40 0.52% 13
2025
Q2 		$1.14M Hold
53,733
– – 0.34% 14
2025
Q1 		$771K Hold
53,733
– – 0.23% 15
2024
Q4 		$1.19M Hold
53,733
– – 0.31% 14
2024
Q3 		$752K Hold
53,733
– – 0.18% 15
2024
Q2 		$1.07M Hold
53,733
– – 0.27% 15
2024
Q1 		$2.55M Hold
53,733
– – 0.06% 14
2023
Q4 		$2.42M Hold
53,733
– – 0.06% 14
2023
Q3 		$2.28M Hold
53,733
– – 0.84% 15
2023
Q2 		$3.32M Hold
53,733
– – 1.03% 12
2023
Q1 		$5.78M Hold
53,733
– – 1.88% 12
2022
Q4 		$7.15M Hold
53,733
– – 2.08% 12
2022
Q3 		$4.28M Hold
53,733
– – 1.26% 13
2022
Q2 		$5.34M Hold
53,733
– – 1.36% 13
2022
Q1 		$6.49M Hold
53,733
– – 1.23% 13
2021
Q4 		$12.5M Hold
53,733
– – 1.42% 12
2021
Q3 		$16.9M Buy
+53,733
New +$16M 1.48% 11

Other funds holding VOR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Johnson & Johnson's VOR Position: Q2 2026 in Review

Johnson & Johnson held its Vor Biopharma (VOR) position steady in Q2 2026 at 53,732 shares worth $989K. The position accounts for 0.12% of the portfolio, ranked #13.

Johnson & Johnson first reported a position in VOR in Q3 2021 and has held it in 20 quarters since. The position peaked at $16.9M in Q3 2021. 42 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Johnson & Johnson held 53,732 shares of Vor Biopharma worth $989K as of Q2 2026.
  • Johnson & Johnson left its Vor Biopharma share count unchanged in Q2 2026.
  • Vor Biopharma made up 0.12% of Johnson & Johnson's portfolio in Q2 2026, its #13 holding.
  • Johnson & Johnson first reported a position in Vor Biopharma in Q3 2021 and has held it in 20 quarters since.
  • Johnson & Johnson's Vor Biopharma position peaked at $16.9M in Q3 2021.
  • 42 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Johnson & Johnson's 13F filing for Q2 2026, filed 6 Aug 2026.